

**In the Claims:**

Kindly cancel claims 1-24 without prejudice or disclaimer and add the following new claims:

---

12/ 25. (New) A LL2 monoclonal antibody (mAb) or fragment thereof comprising complementarity-determining regions (CDRs) and framework (FR) regions, wherein the CDRs of the light chain variable region of said LL2 mAb comprise CDR1 comprising amino acids 24 to 40 of SEQ ID NO: 2, CDR2 comprising amino acids 56 to 62 of SEQ ID NO: 2 and CDR3 comprising 95 to 102 of SEQ ID NO: 2 and the CDRs of the heavy chain variable region of said LL2 mAb comprise CDR1 comprising amino acids 31 to 35 of SEQ ID NO: 4, CDR2 comprising amino acids 50 to 66 of SEQ ID NO: 4 and CDR3 comprising 99 to 105 of SEQ ID NO: 4.

26. (New) The LL2 or fragment thereof of claim 25, further comprises:

- a) at least one FR of at least one light and heavy chain variable region of a human antibody;
- b) the light chain constant region and the heavy chain constant region of one or more human antibodies or
- c) a combination of a) and b).

27. (New) The LL2 mAb or fragment thereof of claim 26, wherein said FRs of the light and heavy chain variable regions of said LL2 mAb comprise at least one amino acid substituted from said corresponding FRs of a murine LL2.

---